Healthcare Industry News:  Decipher Prostate RP 

Diagnostics Oncology

 News Release - February 22, 2018

GenomeDx Announces Inclusion of Decipher Genomic Testing in NCCN Guidelines for Prostate Cancer

Decipher testing recognized as standard-of-care in management of prostate cancer patients

SAN DIEGO, Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced that its Decipher® Prostate Biopsy and Decipher Prostate RP molecular assays for prostate cancer are now included in the 2018 National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology [Version 1.2018].

The NCCN Guidelines are the recognized clinical standard for cancer care, and are developed and revised by a panel of expert physicians from 27 leading U.S. cancer centers. The panel revises recommended practice guidelines according to current evidence and advances in cancer care.

Decipher is now standard-of-care pursuant to NCCN Guidelines for 125,000 prostate cancer patients in the following indications:

  • Decipher Prostate Biopsy -- to help guide treatment for men diagnosed with early-stage, localized prostate cancer, specifically in both the low and favorable intermediate risk categories of prostate cancer. These men may be suitable candidates for active surveillance or observation rather than immediate and invasive therapy, such as radiation or surgery.

  • Decipher Prostate RP -- in the treatment pathway for men considering radiation who have detectable levels of Prostate Specific Antigen (PSA) after a Radical Prostatectomy (surgical removal of the prostate). Decipher Prostate RP is the only molecular test included in NCCN Guidelines for post-operative patient management, and helps identify men who may need additional therapy to minimize risk of metastasis.

By using Decipher to decode the genomic information of a patient's tumor, physicians are better equipped to guide men in deciding whether invasive treatments can be safely avoided or deferred. Many of such treatments may dramatically impact a man's sexual function, continence and overall quality of life.

"We are thrilled with the inclusion of both Decipher Prostate Biopsy and Decipher Prostate RP in the NCCN Guidelines for prostate cancer," said Doug Dolginow, M.D., chief executive officer of GenomeDx. "We believe this significant milestone will contribute to further adoption of our Decipher molecular assays and drive increased coverage among public and private payers."

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading U.S. cancer centers devoted to patient care, research and education, is dedicated to improving the quality, effectiveness and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As an arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians and other health care decision-makers.

About Decipher Cancer Classifier Tests and GRID

GenomeDx's Decipher prostate and bladder cancer classifiers are clinical, commercially available oncology tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher RP is indicated for men after prostate removal surgery, and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to help determine which patients may be more likely to benefit from additional treatment.

The Decipher tests are derived from GenomeDx's Decipher Genomics Resource Information Database (GRID). GRID contains the genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. Each tumor analyzed with a Decipher test adds new data to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID make genetic information accessible for researchers to predict responses to therapy better and to guide treatment more precisely. In addition, GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.

Learn more at and

About GenomeDx Biosciences

GenomeDx is reimagining the use of genomics as a platform for mass collaboration to improve patient treatment and outcomes through its currently available genomic tests for prostate and bladder cancer as well as potential future tests. GenomeDx has offices in Vancouver, British Columbia and San Diego, California.

Learn more at

Source: GenomeDx Biosciences

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.